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Abstract: Interprofessional care for chronic kidney disease facilitates the delivery of high quality,
comprehensive care to a complex, at-risk population. Interprofessional care is resource intensive and
requires a value proposition. Joint Commission certification is a voluntary process that improves
patient outcomes, provides external validity to hospital administration and enhances visibility to
patients and referring providers. This is a single-center, retrospective study describing quality
assurance and performance improvement in chronic kidney disease, Joint Commission certification
and quality outcomes. A total of 440 patients were included in the analysis. Thirteen quality indicators
consisting of clinical and process of care indicators were developed and measured for a period of
two years from 2009–2017. Significant improvements or at least persistently high performance were
noted for key quality indicators such as blood pressure control (85%), estimation of cardiovascular
risk (100%), measurement of hemoglobin A1c (98%), vaccination (93%), referrals for vascular access
and transplantation (100%), placement of permanent dialysis access (61%), discussion of advanced
directives (94%), online patient education (71%) and completion of office visit documentation (100%).
High patient satisfaction scores (94–96%) are consistent with excellent quality of care provided.
Keywords: chronic kidney disease; interprofessional care; quality assurance
1. Introduction
Interprofessional (IP) care for chronic kidney disease (CKD) facilitates the delivery of
comprehensive care to a complex, at-risk population. Evidence based strategies for slowing progression
of CKD are well described but not consistently applied to the individual patient. Interprofessional
teams focus on implementing evidenced based care to slow down the progression of CKD, educating
patients about their disease and streamlining the transition to end stage renal disease (ESRD).
This comprehensive care has been shown to reduce hospitalizations [1–6] lower mortality [1,3,4,7–9],
slow the progression of CKD [1–3,10,11] and prepare patients for transitions in care [4,7,8]. Despite
these benefits, IP CKD programs are difficult to implement because of resources. Advocates of IP care
should provide evidence of value to justify the additional cost since CKD consumes a disproportionate
share of healthcare funding globally [12,13]. The Joint Commission (TJC) certification is a voluntary
process that can improve patient outcomes, provides external validity to hospital administration and
enhances visibility to patients and referring providers. In this paper, we describe the development of
an IP CKD program and the pathway to TJC disease specific certification in CKD care.
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2. Materials and Methods
This is a retrospective, single center study of all adult patients receiving care in the IP CKD
Program from July 2011–2016. We included all adult patients with CKD receiving IP care. Patients
with less than 3 months of follow up in the program were excluded from the analysis. Clinical data
including patient demographics, comorbidities, laboratory results, vital signs measured during clinic
visits, medications, process of care measures as well as outcomes of dialysis initiation, transplantation
or death were extracted from the electronic health record (EHR). To analyze patient demographics
and performance measures for each recertification cycle, we used descriptive statistics including mean
and standard deviation (SD) or median and range for continuous data when appropriate, frequency
counts and percentage for categorical data. Descriptive statistics were calculated using R version (3.4.2).
The institutional review board (IRB) for human subjects approved this study with a waiver of consent.
2.1. Program Description
The pharmacist wrote the proposal for the IP CKD Program and obtained funding from the health
system. This program was set up as its own cost center and the pharmacist funding is supported by the
health system for direct patient care and administration of the CKD program. The nephrologist and
pharmacist created the infrastructure for the program including a mission statement, clinic schedules,
job descriptions, template notes and standard orders. Our institutional IP CKD Program opened in
2007 and provides comprehensive care to patients with CKD stage 2 through 5. Patients are referred for
IP care by a nephrologist or through direct referral from other disciplines. The program does not have
specific referring criteria; rather any patient who the referring physician feels would benefit from IP
CKD care is eligible. The program consists of two half-day clinics, which operate in the same physical
space as other nephrology clinics. Patients are seen every 1 to 6 months depending on disease severity.
Visits are approximately 90 and 45 min for new and return patients, respectively. The core IP team
consists of a nephrologist/medical director, pharmacist/program administrator, nurse, dietitian, social
worker and patient education coordinator. Interprofessional care is provided based on institutional
CKD guidelines and documented in the EHR. Chronic kidney disease guidelines were developed
using Kidney Disease Improving Global Outcomes (KDIGO) guidelines, Kidney Disease Outcomes
Quality Initiative (KDOQI), Joint National Commission hypertension guidelines, American Diabetes
Association diabetes care guidelines, American Heart Association guidelines as well primary and
tertiary references [14–69]. These were approved by our institutional Pharmacy and Therapeutics
Committee and updated annually.
Patients receive many services in addition to the traditional nephrology care such as cardiovascular
risk assessment, dietary counseling on CKD diet, weight loss, vaccinations, smoking cessation,
medication reconciliation and management, personalized medication schedules, assistance with
insurance and transportation issues as well as assistance with transition of care to transplant, dialysis or
hospice (Appendix A). Patient education is provided during each visit on an individual basis, through
online educational videos (https://www.youtube.com/playlist?list=PLp5o_4MxOoYRJ_zYObvWzC-
O0VE7wFqaG) and in a classroom setting. Educational topics include introduction to CKD, medications
and CKD, diet, social support networks, renal replacement modalities and transplantation.
Each team member has defined roles and responsibilities to optimize patient care. All members
of the IP team receive orientation to the program and institutional CKD guidelines. Team members
are evaluated for competency initially and must demonstrate continuing competency and education
annually. Competency is assessed verbally and through the demonstration of skills where appropriate.
Team members answer questions about mini case scenarios to test their knowledge of CKD staging,
overall goals of care based on CKD stage, laboratory parameters and foods high in phosphorus and
potassium. Skills such as blood pressure measurement or administration of medications are evaluated
by demonstration. Contemporary topics in CKD care are reviewed during a mandatory monthly
journal club. The Medical Director and Program Administrator conduct annual performance reviews
for all team members incorporating 360-degree feedback from team members.
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2.2. Design of Quality Assessment and Performance Improvement Program (QAPI) and CKD Registry
The IP team determined appropriate quality indicators consisting of clinical, process and financial
measures such as blood pressure (BP) control, prevalence of permanent vascular access at dialysis
initiation, vaccination rates, patient education among others (Table 1). These measures were chosen on
the basis of their importance for delaying CKD progression, streamlining transitions in care, improving
patient experience and applicability to the majority of the program population. Each quality indicator
was defined, baseline and targets established and strategies were developed to achieve target goals.
For example, we defined BP control as the percentage of patients achieving the target BP per Joint
National Committee guidelines. We established our baseline rate of control and set a target for
improvement. Strategies to achieve the target included medical assistant education on performing
a BP measurement, providing home BP monitors and logs to patients for home monitoring, patient
education and nursing telephone follow up for patients with uncontrolled hypertension.
We developed a CKD registry in the EHR enabling the automated reporting of CKD outcomes.
Data is electronically extracted and presented in a QAPI dashboard, which is reviewed on a monthly
basis by the IP team and submitted to TJC. All outliers are reviewed in detail during the monthly team
meeting and new strategies to achieve targets are developed on an as needed basis.
Table 1. Summary of performance measures.
Indicators Type/Definition Target Goal Rationale Time Period ofImplementation
Systolic and
diastolic blood
pressure
Clinical
Median SBP and
DBP values.
SBP < 130
DBP < 80
The control of blood pressure in the
United States continues to be
suboptimal. Among adults with
hypertension, 48% were at goal [70].
Control of blood pressure is associated
with a reduction in cardiovascular
morbidity and mortality and slower
CKD progression.
2009–2011
BP Control
Clinical
Percentage of office visits
with systolic blood
pressure at goal according
to national guidelines.
Positive trend 2011–2015
Hemoglobin ClinicalMedian hemoglobin value. 10.5–12 g/dL
The target hemoglobin in CKD is
controversial [17,38]. Studies have
demonstrated that normalizing the
hemoglobin value with erythropoietin
stimulating agents results in increased
risk of cardiovascular morbidity
and mortality.
2009–2011
Pneumococcal
vaccinations
Clinical/Percentage of
patients with documented
vaccination with Prevnar
13® and Pneumovax 23®.
Positive trend
Patients with CKD are at increased risk
of pneumococcal infection and
vaccination is recommended by the
Centers for Disease Prevention
and Control [71].
2011–2013
Fistula at time of
dialysis initiation
Clinical/Percentage of
patients starting
hemodialysis with
arteriovenous fistula (AVF)
in place.
Positive trend
AVF use for hemodialysis is associated
with improved morbidity and mortality
and lower costs compared to the use of
a central venous catheter. Despite this,
use of CVC nearly exceeds 80% in
patients initiating hemodialysis.
In 2006, the Centers for Medicare and
Medicaid set a 66% national prevalent
AVF goal, resulting in improvements in
prevalent but not incident hemodialysis
patients [72,73].
2013–2017
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Table 1. Cont.
Indicators Type/Definition Target Goal Rationale Time Period ofImplementation
Vascular access and
kidney transplant
referral
Process of Care/Percentage
of medically appropriate
patients with
eGFR < 20 mL/min/1.73 m2
with referral to vascular
access and/or
transplantation.
Not all patients are
transplant candidates and
we use criteria from the
transplant program to
screen for referral
(i.e., age less than 70 years,
no active cancer in the past
5 years and adherent to
therapies). Patients who
decline dialysis and/or
chose palliative care are
not referred to
vascular surgery.
Positive trend
Standardizing the referral process for
vascular access and transplantation
using specific criteria would improve
rates of timely and
appropriate referrals.
2009–2011
Advanced
Directives
Process of Care/Percentage
of patients with whom
advanced directives
were discussed.
Positive trend
Nephrologists caring for CKD patients
are in a position to discuss transitions in
care and patient preferences.
2011–2013
Patient Education
Process of Care/All new
patients receiving
education on CKD within
3 months of entering
the program.
Positive trend
Patient education can increase
knowledge of CKD progression and
complications with the goal of
increasing patient engagement.
2009–2011
Process of Care/Online
education viewing. 2015–2017
Testing of
Hemoglobin A1c
Process of Care/All
patients with DM and
CKD stage 2–5 with
HgA1c tested in last
6 months.
90%
Tight control of glucose is associated
with a reduction of microvascular and
macrovascular complications. Patients
with controlled diabetes should have
HgA1c checked every 6 months and if
uncontrolled every 3 months [61].
2015–2017
Access to care Process of Care/Mediandays to first appointment. Negative trend
Two half day clinics limits the number
of visits. Patients experienced long
waiting periods from referral to first
appointment.
2013–2015
ASCVD risk
estimation
Process of Care/Percentage
of patient visits with
ASCVD risk estimated
and documented.
Positive trend
Cardiovascular disease is the leading
cause of death in patients with CKD.
The ASCVD risk calculator provides an
estimate of a patient’s risk for a
cardiovascular event with the goal of
reducing the risk with medical
management and lifestyle
modification [74].
2015–2017
Cancellation rate
Financial/Percentage of
office visits cancelled by
patients.
Negative trend
Patients with CKD have numerous
barriers to their access to care.
Evaluating the clinic cancellation rate
and reasons may improve the
appointment process and access to
CKD care.
2011–2013
Encounter
documentation
Financial/Percentage of
office visit encounters with
complete documentation
within 48 h.
Positive trend Complete encounter documentation isrequired to effectively bill for services. 2013–2015
BP = blood pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure, CKD = chronic kidney
disease, AVF = arteriovenous fistula, CVC = central venous catheter, eGFR = estimated glomerular filtration rate,
DM = diabetes mellitus, ASCVD = atherosclerotic cardiovascular disease.
3. Results
A total of 440 patients currently receive care in the IP CKD program. The demographics are
summarized in Table 2.
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Table 2. Patient demographics.
Characteristic n = 440
Age, years (mean ± SD) 64.2 ± 14.5
Gender, Male (%) 55
Ethnicity, Hispanic (%) 24
CKD Stage (%)
1–2 8
3 51
4 24
5 17
Urine protein to creatinine ratio, mg/mg (median, range) 325 (0–31,552)
Co-morbidities (%)
Diabetes 50
Hypertension 92
The mean age of the population is 64.2 ± 14.5 years, 55% are male and the majority are White with
24% Hispanic patients as the second largest ethnicity. The majority of patients are in CKD stage 3 (51%)
followed by stage 4 (24%) and stage 5 (17%). Approximately half of the patients have diabetes and 92%
have hypertension.
Prior to the first certification in 2010, we chose the following quality indicators: (1) blood pressure
control (median systolic and diastolic blood pressure, percent of patients with SBP ≤ 130 mmHg,
percent of patients with SBP ≤ 140 mmHg), (2) median hemoglobin, (3) screening for appropriate
patient referrals to vascular surgery and transplant and (4) percent of patients with education about
CKD within 3 months of clinic enrollment (Table 3).
Table 3. Performance measurement report: 2009–2011.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 190 219 198 199 191 199 208 216
Median SBP (mmHg) 136 137 135 132 127 131 133 131
Median DBP (mmHg) 73 74 74 70 70 72 73 72
Median Hemoglobin (g/dL) 11 11 12 11 12 11 11 11
Patients with Referral to Vascular Surgery (%) 96 100 96 100 100 100 91 100
Patients with Referral to Transplant Program (%) 88 100 100 100 100 100 81 100
Patients Attending Patient Education Classes (%) 29 33 50 50 100 100 100 100
CKD = chronic kidney disease; DBP = diastolic blood pressure; SBP = systolic blood pressure.
We collected 6 months of data on those measures for the initial certification. The range of median
systolic blood pressure was 127–137 mmHg, 36–44% of patients had SBP ≤ 130 mmHg, and 56–76%
of patients had SBP ≤ 140 mmHg. Eighty-eight to 100% of patients had an appropriate referral to
vascular surgery or transplantation. The percentage of patients who received in classroom CKD
education within the first 3 months of joining the clinic steadily rose from 33% to 50%. We received
Disease Specific Certification for CKD with no findings for improvement and were noted to be the
first program in the United States with this designation. After receiving our certification, our surveyor
invited us to present our program outcomes to the Quality Net Conference for the Centers for Medicare
and Medicaid.
In the first recertification cycle 2011–2013, we chose the following indicators: (1) SBP ≤ 130 mmHg
(2) pneumococcal vaccination rate (3) discussion of advanced directives (4) office visit cancellation rate
(Table 4).
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Table 4. Program performance measurement report: 2011–2013.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 209 210 223 227 228 214 211 225
Patients with SBP ≤ 130 mmHg (%) 57 54 51 51 45 47 49 58
Patients with SBP ≤ 140 mmHg (%) 79 88 79 85 75 74 79 82
Patients with Pneumococcal Vaccine (%) 49 61 69 84 88 89 93 93
Patients with Advanced Directive Addressed (%) 29 75 94 93 94 93 93 89
Office Visit Cancellation Rate (%) - 28 25 19 23 22 25 21
SBP = systolic blood pressure.
Tight control of SBP ≤ 130 mmHg was achieved in 47–58% of patients and SBP ≤ 140mmHg was
obtained in 74–85% of patients. Pneumococcal vaccination included Prevnar 13 and Pneumovax 23
and the rate rapidly rose from 49% in the first quarter to 93% in the last quarter of the cycle, as did the
percentage of patients who discussed advanced directives with our social worker, from 29% to 94%
over a two-year period. We were not able to sustain a decrease in the rate of cancellation of office visits
after an initial drop from 28% to 19%.
In the second recertification cycle 2013–2015, we chose the following quality indicators: (1) SBP ≤ 130
and 140 mmHg (2) percentage of patients starting hemodialysis (HD) with AVF or arteriovenous graft
(AVG), (3) median days from referral to first appointment in CKD clinic and (4) percent of office notes
closed in EHR within 48 h (Table 5).
Table 5. Performance measurement report: 2013–2015.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 240 234 241 156 256 259 223 136
Patients w/SBP ≤ 130 mm Hg (%) 53 56 55 55 - - - -
Patients w/SBP ≤ 140 mm Hg (%) 81 84 82 85 85 79 82 83
Patients w/AVF or Graft at Dialysis Start (%) 100 100 100 100 60 25 75 50
Median Days from Referral to First Appointment 17 13 7 7 9 37 12 14
Notes Closed within 48 h (%) 45 98 96 99 92 95 98 100
AVF = arteriovenous fistula, SBP = systolic blood pressure.
In December 2013, the Joint National Commission released new guidelines recommending a blood
pressure goal of ≤140 mmHg and we decided to stop tracking the SBP goal ≤130 mmHg. We achieved
SBP control to ≤140 mmHg in 79–85% of patients. The percentage of patients starting dialysis with
AVF or AVG varied from 25 to 100% in different quarters with overall average of 77%. The median
wait time from referral to first CKD clinic appointment varied from 7 to 37 days. The percentage of
note closure within 48 h improved from 45% to 100%.
In the third recertification cycle 2015–2017, the following quality indicators were chosen: (1) patient
viewing of online education videos, (2) continuation of permanent dialysis access indicator, (3) ordering
of hemoglobin A1c every 6 months for patients with diabetes and (4) estimation and documentation of
atherosclerotic cardiovascular disease (ASCVD) risk (Table 6).
Table 6. Performance measurement report: 2015–2017.
Reporting Year 1 Reporting Year 2
Performance Indicators Jul-Sep Oct-Dec Jan-Mar Apr-Jun Jul-Sep Oct-Dec Jan-Mar Apr-Jun
All patients (N) 216 252 219 247 224 225 212 243
% Patients w/AVF or Graft at Dialysis Start 100 89 50 100 0 44 56 50
% Patients w/Online Patient Education 0 10 25 35 48 55 64 71
% Patients w/DM and HgA1c Order within 6 mo 90 94 90 93 89 91 97 98
% Patients w/ASCVD Risk Documentation 82 100 99 100 98 99 100 100
ASCVD=atherosclerotic cardiovascular disease; AV = arteriovenous fistula, DM = diabetes mellitus, HgA1c = glycated
hemoglobin, mo = months.
Fifteen patient education videos were created to improve treatment adherence, self-care,
and clinical outcomes for CKD patients. CKD team members, including the nephrologist, pharmacist,
dietitian, and social worker, each created several 5–15 min videos on specific topics related to CKD
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patient care that were peer reviewed by all team members. The videos were filmed in English at
a production studio located on the main university campus. The entire process of video planning
and filming took three months. After production of videos was complete, a CKD playlist of videos
was created and published on YouTube (https://www.youtube.com/playlist?list=PLp5o_4MxOoYRJ_
zYObvWzC-O0VE7wFqaG). A link to the videos was shared through e-mail, EHR patient messaging
and posted on the CKD program website. A brochure advertising the videos was created and
distributed to patients in clinic and through mail. For patients without computers, internet access,
or mobile phones, a DVD was distributed in clinic or the video was played for the patient on clinic
computers. Each patient was asked about video views during the office visit and this was documented
in the EHR using smart fields for electronic data extraction. There was a steep and consistent increase in
the percentage of patients viewing our online education videos from 0 to 71%. The 15 videos received
a total of 284,808 views and the total number of views per videos ranged from 276 to 132,710 far
surpassing our patient population. Videos with the highest views included content on: (1) symptoms
of kidney disease (132,710 views), (2) stages of kidney disease (91,265 views), and (3) laboratory values
of kidney disease (18,615 views).
For the other quality indicators, the percentage of permanent dialysis access at dialysis initiation
was 0–100% (median 61%), and, the number of patients starting dialysis was low ranging from 0–3 per
month. Hemoglobin A1c testing was high at baseline at 90% and remained consistently high with a
range of 89–98%. ASCVD risk was not routinely documented in office visit notes at baseline. After
implementation of an automated ASCVD risk estimate calculator in the EHR, we demonstrated an
immediate increase in documentation to 82% in the first quarter of implementation and subsequent
increase to 100% documentation. We received re-certification with no findings for improvement and
positive feedback on the successful development of online education for patients with CKD.
Patient satisfaction was measured using The Consumer Assessment of Health Providers and
Systems surveys administered by Press Ganey and collected for each certification and recertification
cycle. From 2012 to present, the percentage of surveys where patients reported “yes, definitely” on a
3-point scale for their likelihood to recommend the program and the physician communication domain
were approximately 94% and 96%, respectively.
4. Discussion
In this study, we demonstrated that IP care for CKD could be implemented and sustained over a
long time period at an academic institution. The process of obtaining TJC certification is educational
and rewarding. It provides opportunity to examine program performance and identify gaps in care.
TJC certification ensures an ongoing process of quality measure development, implementation of
interventions to achieve program goals and measurement of outcomes. In contrast to other regulatory
agencies, TJC certification provides flexibility for programs to determine their own meaningful measures
of performance. Over the past eight years, we have defined and measured 13 quality indicators for
CKD care. Overall, we were able to improve performance on the majority of quality indicators or at
least maintain the high performance. Most indicators were retired at the end of the recertification cycle.
Some were considered critical to CKD care and were continued in additional cycles.
4.1. Blood Pressure Control
Blood pressure control remained a performance measure for 3 cycles of recertification since it is
essential to preventing CKD progression and we found opportunity for performance improvement.
On average, blood pressure control was achieved in 81% of patients. When we targeted a more
stringent goal (<130/80 mmHg), between 53–67% of our patients were able to achieve that target.
Despite a drop in control with implementation of more stringent targets, we still achieved higher
rates of control compared to the literature. Thanamayooran and colleagues demonstrated that 40% of
patients achieved a target blood pressure of <130/80 mmHg when receiving IP CKD care [75]. Surveys
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of the general population have demonstrated that 13.2–37% of patients with CKD achieve a target
blood pressure [76,77].
Achieving a target clinic blood pressure proved to be challenging. To improve blood pressure
control, the entire IP team was engaged in numerous aspects. Our medical assistants have yearly
competency evaluation on accurate blood pressure measurement and ensure elevated blood pressure
measurements are repeated and recorded. The dietitian counsels on dietary sodium restriction and
educates patients on how to read food labels. The pharmacist assesses medication adherence, adverse
effects of antihypertensives and optimizes therapy. Nurses perform routine telephone follow up on
home blood pressure measurements for patients whose clinic measurements are not at goal. The social
worker assesses financial resources and addresses barriers to medication access and provides a free
blood pressure monitor to patients in need. The physician reviews the team recommendations,
summarizes a plan that optimizes the antihypertensive regimen and includes principles of healthy
lifestyle (regular exercise, low sodium diet, limiting alcohol intake, etc.). Over 90% of our patients
monitor and log home blood pressure, which facilitates medication adjustment based on home
readings. A significant number of patients have a white coat hypertension, so the use of clinic readings
underestimates true blood pressure control [28,70]. With the implementation of and increased patient
engagement in the EHR, it may become possible to report performance based on home readings.
Future initiatives for blood pressure control include having patients enter their home readings into
the MyChart portal of the EPIC EHR using their mobile device or laptop so values are recorded and
actionable. We have not yet implemented this blood pressure initiative due to a lack of educational
materials and resources to educate patients on this electronic reporting.
4.2. Education
Education on CKD is critical in empowering patients to be active participants in their care and
has been associated with decrease in hospitalizations and mortality [1,3–5,7,8,11]. In a prospective,
randomized, controlled trial of an IP CKD educational intervention, the IP care group showed a
significant delay in initiation of dialysis therapy compared to the usual care group (p < 0.0001) [78].
Pre-dialysis education is important in assuring a smooth transition to dialysis including placement
of permanent access and/or transition to transplantation [79]. Peritoneal dialysis (PD) and home
hemodialysis (HD) are underutilized in the United States with ~90% of patients receiving in-center
HD [80]. We believe that extensive education provided to our patients was the reason for a relatively
high percent of our patients starting renal replacement therapy with PD (30%) compared to in-center
HD (70%). This is consistent with other studies that showed that CKD education is associated with
increased selection of home HD and PD modalities as opposed to in center HD [81]. In a survey of
practicing nephrologists, over 90% of the nephrologists would choose home dialysis for themselves,
yet few CKD patients are on home dialysis therapy [82]. Clinicians should apply the same standards
for taking care of patients that they would desire for themselves or family members, should they
develop ESRD. Various medical programs are increasingly adopting technology solutions to support
self-management practices [83,84]. We were able to educate many more patients with online videos
than group classes (70% vs. 33% respectively). Online education provides the solution to several
barriers faced with in-person education including transportation to the facility, scheduling, learning
pace (i.e., patients can watch videos at their convenience and pace), and frequent physician visits or
hospitalization. One major limitation is the production of videos in different languages. Due to limited
resources, we did not translate the education videos into Spanish; consequently, not every patient
benefited from the videos.
4.3. Vascular Access
Timely permanent access creation for chronic dialysis is complicated by numerous clinical and
psychosocial factors making this an important but challenging quality metric. Use of AVF for HD is
associated with improved mortality and morbidity and lower cost compared to the use of a central
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venous catheter [10,72,85]. Over the last decade, the rate of AVF use in prevalent dialysis patients has
improved significantly from approximately 35% to 65% [80]. However, at dialysis initiation, AVF use
continues to be very low with over 80% of patients initiating dialysis using a tunneled catheter [80].
Emergent start of dialysis continues to be too common and likely contributes to high mortality and
morbidity in the first 6 months of starting dialysis, especially in patients over 65 years of age [80].
Early in our program development, we experienced significant delays from patient referral to
vascular surgery to the actual visit and/or placement of permanent vascular access. In order to
address this problem, we created a joint CKD-vascular surgery clinic, scheduled once a month, where
patients who had advanced CKD could see the nephrologist and surgeon during the same visit.
This coordination of care resulted in timely vascular access evaluation and surgery. On average,
77% of patients started HD with a functional AVF in the first 2-year cycle and 61% in the second
cycle. One challenge we encountered with this quality indicator is the small number of patients who
transition from CKD stage 5 to HD making it difficult to compare and trend month-to-month data
or to demonstrate significant improvement. Our results are similar to other studies demonstrating
higher AVF rates of 45.2–68.4% in patients receiving IP CKD care compared to 4.8–58.8% in the usual
care groups [1,4,86,87]. Despite receiving comprehensive education and IP care, there are patients
who will start HD with a tunneled catheter for multiple reasons including: (1) late referral of patients
with advanced CKD and low socioeconomic status, (2) emergent dialysis for acute kidney injury in
patients who previously had moderate (not advanced) CKD at baseline and (3) patients who initially
choose peritoneal dialysis, yet start with HD due to unforeseen acute deterioration in health. We are
developing and implementing a protocol for urgent start PD (within 24–48 h after placement of PD
catheter) to address the latter problem.
4.4. Transplantation
Survival rates for patients with ESRD are much better for those undergoing kidney transplantation
compared to those receiving chronic dialysis [80]. Our program ensures timely referral of appropriate
candidates to the transplant program once the GFR approaches 20 mL/min/1.73 m2. Our experience is
that patients from our CKD IP program have better health related outcomes (i.e., health maintenance,
self-monitoring of health outcomes and medication adherence) and experience a higher likelihood of
placement on the transplant waiting list (not reported). However, we have not measured and compared
our referral to listing ratios to that of usual nephrology care. Some patients receive preemptive kidney
transplantation while others start accruing waiting time prior to initiation of dialysis (i.e., once the
GFR is below 20 mL/min/1.73 m2). To facilitate transplant referral, we have worked with the transplant
program and informatics team to enable the clear and visible display of transplant listing status in each
patient’s EHR.
4.5. Vaccinations
Vaccinations are one of the most beneficial health prevention strategies to reduce morbidity and
mortality associated with communicable infections. Patients with CKD should receive an annual
influenza vaccine, pneumococcal and hepatitis B vaccinations [71]. We focused on pneumococcal
rather than hepatitis B vaccination since our baseline rate for hepatitis B vaccination was high whereas
there was an opportunity for improvement in pneumococcal vaccination rate. To improve this measure,
we ensured accurate documentation of vaccination history by the pharmacist for every patient and
we streamlined the vaccination ordering process. We experienced a robust increase in pneumococcal
vaccine administrations from a baseline of less than 50% to over 90% patients at the end of the
reporting cycle.
4.6. Advanced Directives
During the re-certification process, there is opportunity to discuss the retirement of measures
and adoption of new quality measures. Our Joint Commission surveyor felt that providers in IP CKD
Pharmacy 2019, 7, 83 10 of 18
clinic are in a unique position to discuss transitions in care and patient preferences and suggested
we start tracking discussions about advanced directives with our patients. Discussion of advanced
directives can be uncomfortable especially in an ambulatory care setting and with younger patients.
Our social worker felt best prepared and positioned to lead the discussions with patients. Despite
our perceived concerns around this measure, we were able to initiate conversations about advanced
directives in 90% patients, which was a significant improvement from a baseline value of less than 30%.
In 2015, Medicare spending exceeded $64 billion for beneficiaries with CKD and $34 billion for ESRD
costs totaling over $98 billion [80]. The cost is disproportionally high for dialysis patients in the last
year of their life. Discussing advanced directives with pre-dialysis and dialysis patients is critical to
select medical interventions that are aligned with patient preferences, while reducing unnecessary cost
to society.
4.7. Cardiovascular Disease Risk
Cardiovascular disease (CVD) remains the leading cause of death in the United States and most
other developed countries [88]. Among patients with CKD, death from CVD is far more common
than progression to ESRD. CKD has been identified as an independent risk factor for CVD, even after
adjustment for usual comorbid conditions [74]. The risk for CVD increases as GFR declines [80,89].
Assessing the risk is critical given high prevalence and poorer prognosis after a CV event in patients
with CKD compared to general population (i.e., adjusted two-year survival of patients with acute
myocardial infarction is 81% in general population, compared to 56% for CKD Stage 4–5 [80]. Estimating
risk for CVD in patients with CKD is complicated due to the presence of traditional and non-traditional
cardiac risk factors. Online and smart phone risk calculators have been developed by the American
College of Cardiology, available: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/
(Last Accessed: 6/25/18). We worked with the informatics team to implement an electronic ASCVD
risk calculator in the EHR, resulting in a quick and steep increase in documentation of this important
risk from zero to 100% by the end of the reporting cycle. Patients with high ASCVD risk receive
additional attention in terms of education on the importance of lifestyle modifications, appropriate
medical management and referrals to cardiology.
4.8. Other Indicators
For other indicators, we were successful in improving the rate of completion of office visit
documentation in the EHR within 48 h of the office visit from below 50% to approximately 100%.
We ensured that over 90% of diabetic patients had HgA1C checked at least every 6 months. We did not
make much improvement in some process measures like clinic cancellation rate or access to care due to
numerous factors outside of our control.
4.9. Challenges
Upfront cost of an IP team is the biggest challenge to implementing and maintaining IP CKD care.
The standard fee-for-service model in the United States does not reimburse many team members other
than physicians or advanced practice professionals (physician extenders). Dieticians are reimbursed by
Medicare for evaluating patients with CKD stage 4, though we encountered logistical challenges with
scheduling patients for two separate visits (with the physician and dietician) during the same CKD
visit, obtaining insurance authorization for each visit with the dietitian and placing a physician referral
to the dietician for each subsequent visit. Medicare provides reimbursement for 6 educational sessions
on dialysis modalities, but these sessions must be of at least 30 minutes duration and provided by a
physician or physician extender. Medication therapy management services provided by the pharmacist
are not reimbursable under the current Medicare structure since the CKD visit is done in conjunction
with the physician. Social worker services are not reimbursable unless counseling is provided for a
mental health condition. However, IP CKD programs have a potential for creating downstream or
indirect revenues by increase in outpatients starts of dialysis, more patients starting dialysis with a
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permanent access, more PD utilization, improved referrals for living kidney donor transplantation and
in turn higher rates of transplantation. All of those help to offset the cost of IP care or even make IP
CKD programs cost effective.
In 2015, Medicare ESRD expenditure/person/year was $88,750 for a HD patient, $75,140 for a PD
patient and $34,084 for a transplant patient [80]. Patients who receive dialysis with AVF have a lower
total cost/member/year compared to those with HD catheters [80]. More recently, Lin and colleagues
evaluated the cost-effectiveness of a theoretical IP CKD program compared to usual CKD care in U.S.
Medicare beneficiaries with stage 3 and 4 CKD between the age of 45 and 84 years. The results of the
model showed that a Medicare-funded IP CKD program could be cost effective by decreasing the need
for RRT and prolonging life [13].
Space may also pose a challenge when developing a new program. We initially secured space by
sharing the same clinic space and time allocation as the general nephrology clinics. This was not as
challenging compared to securing new space as part of our goals to expand the program. We struggle
with obtaining new space to add additional clinics in other geographic locations to better serve our
diverse patient population.
4.10. Limitations of Our Study
There are several limitations to our study. This is an observational, descriptive study evaluating
the impact of Joint Commission certification and recertification on clinical and process of care outcomes
for patients with CKD. Since there was no control group in this study, it is possible that clinical
outcomes achieved in this program could be achieved in a physician-based clinic. However, various
team members led many of the quality improvement projects (i.e., vaccination rates by pharmacist,
advanced directives by social worker, permanent dialysis access by a nephrologist) and it is unlikely
that one team member alone could do all of it. This shared approach was critical to our success and
this degree of quality improvement would not likely be sustained over a long period of time in a
physician-based clinic. Secondly, some of the patients referred to our program received care in the
general nephrology clinic prior to referral and it is possible the previous care had impacted their
outcomes, but this bias may have been in both directions for the outcomes of interest. Lastly, the results
may not be generalizable to non-academic programs given differences in the informatics resources,
patient population and IP team members. Additional research is needed to compare the outcomes and
cost-effectiveness of IP care to usual CKD care and to evaluate the feasibility of disseminating this
model of care to other institutions.
5. Conclusions
Joint Commission certification requires the development and implementation of robust quality
assurance and performance improvement plans. CKD care delivery involves a set complex processes
and improvement in outcome measures are best achieved using a team-based approach where high
quality care is a priority for all IP team members. Achieving certification is not a simple task, it requires
strong leadership, dedication, time commitment and institutional support with the reward of nationally
recognized, external validation of the excellence in care to the patients we serve.
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Appendix A
Table A1. Chronic kidney disease program team roles and responsibilities.
Medical Director
1. Medical history
2. Physical exam
3. Orders for encounter (lab tests, referrals, medications, follow-up)
4. Documentation of visit in EPIC
5. Supervises nephrology fellow and medical residents
6. Supervises interprofessional team
7. Plan and present classes on kidney disease
8. Oversees medical management for CKD population
9. Strategic planning with respect to program growth, outcomes
10. Participate in staff evaluations
11. Attend and direct team meetings
Pharmacist and
Program
Administrator
1. Medication history and medication reconciliation
2. Medication therapy management (evaluate doses for renal function, etc.)
3. Assist with orders for encounter (lab tests, referrals, medications, follow-up)
4. Counsel patient on new medications, medication changes and provide a current list
of their medications
5. Documentation of visit in EPIC
6. Supervises pharmacy residents and students
7. Supervises interprofessional team
8. Plan and present classes on kidney disease
9. Responsible for analyzing and presenting program outcomes
10. Staff recruitment and performance appraisal
11. Lead team meetings
12. Strategic planning with respect to program growth, outcomes
13. Prepare budget annually
Dietitian
1. Evaluate nutritionally relevant information
2. Assess diet and make recommendations for changes in diet or dietary supplements
3. Document assessment, care plan and education in EPIC
4. Plan and present classes in nutrition
5. Create meal plans for individual needs
6. Monitor dietary change and provide feedback
7. Attend CKD team meetings
Case Manager
1. Brief psychosocial assessment on all new patients and document in EPIC
2. Assess for changes on return visits
3. Address any insurance and community resource needs with patients as appropriate
4. For patients in CKD IV or higher, begin discussing dialysis plans, preference for PD
versus HD and location
5. Assist in teaching Modalities (Kidney Treatment Options) class to new patients and
document their attendance and preference in EPIC progress notes
6. Refer patients anticipated to need dialysis for insurance verification
7. Assisting with transition to dialysis
8. Assist with placement in long term facilities or communication with
outside facilities
9. Facilitate communication between patients, CKD team members and other
medicine/surgical disciplines (example vascular access, interventional radiology)
10. For any unfunded or partially funded patients; notify dialysis administrator and
clinical service chief and request temporary acceptance until funding is secured
11. Attend CKD team meetings
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Table A1. Cont.
Nurse
1. Schedules patients into the CKD clinic
2. Triages new referrals to CKD clinic
3. Reviews clinic schedule every week to ensure appropriate numbers of patients
4. Prints out the after visit summary and discharges patient from the visit
5. Reviews next appointment, lab work needed for appointment, procedures, referrals
and medication changes/prescriptions
6. Confirms patients understanding of care plan
7. Administers erythropoietin stimulating agents in clinic when prescribed
8. Administers vaccinations in clinic when prescribed
9. Documents in EPIC
10. Receives patient calls and requests for refills from call center and triages these to
appropriate individuals
11. Attend CKD team meetings
Medical Assistant
1. Takes vital signs on patient (blood pressure, pulse height and weight)
2. Puts the patient into the rooms
3. Notifies CKD team of patient arrival
4. Triages late appointments with Medical Director or Program Administrator
Patient Education
Coordinator/
Administrative
Assistant
1. Schedule team meetings, create agendas and attend meeting
2. Maintain SharePoint site for communications
3. Coordinates all aspects of patient education classes (mailings, patient outreach,
coordinate logistics for rooms, audio-visual, and refreshments, speakers, handouts)
4. Maintains database of all clinic patients
5. Prepare and mail new patient education packets
6. Collect patient data for quality indicators database
7. Maintain office and educational material supplies
8. Program coordinator for 10-week Wellness Program. Responsible for brochure,
mailings, patient outreach, scheduling logistics for rooms, audio-visual, and
refreshments, speakers, handouts
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